282 related articles for article (PubMed ID: 25917633)
1. An update on current and prospective immunotherapies for chronic lymphocytic leukemia.
Emole JN; Locke FL; Pinilla-Ibarz J
Immunotherapy; 2015; 7(4):455-66. PubMed ID: 25917633
[TBL] [Abstract][Full Text] [Related]
2. A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.
de Weerdt I; Lameris R; Ruben JM; de Boer R; Kloosterman J; King LA; Levin MD; Parren PWHI; de Gruijl TD; Kater AP; van der Vliet HJ
Clin Cancer Res; 2021 Mar; 27(6):1744-1755. PubMed ID: 33451981
[TBL] [Abstract][Full Text] [Related]
3. Impairments in immune cell function in B cell chronic lymphocytic leukemia.
Bartik MM; Welker D; Kay NE
Semin Oncol; 1998 Feb; 25(1):27-33. PubMed ID: 9482524
[TBL] [Abstract][Full Text] [Related]
4. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt TD; Ramsay AG; Zent CS; Leis JF; Tun HW; Call TG; LaPlant B; Bowen D; Pettinger A; Jelinek DF; Hanson CA; Kay NE
Blood; 2013 May; 121(20):4137-41. PubMed ID: 23493782
[TBL] [Abstract][Full Text] [Related]
5. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
6. B-cell chronic lymphocytic leukemia-derived dendritic cells stimulate allogeneic T-cell response and express chemokines involved in T-cell migration.
Łuczyński W; Stasiak-Barmuta A; Piszcz J; Iłendo E; Kowalczuk O; Krawczuk-Rybak M
Neoplasma; 2007; 54(6):527-35. PubMed ID: 17949237
[TBL] [Abstract][Full Text] [Related]
7. Vaccine- and immune-based therapy in chronic lymphocytic leukemia.
Le Dieu R; Gribben J
Semin Oncol; 2006 Apr; 33(2):220-9. PubMed ID: 16616069
[TBL] [Abstract][Full Text] [Related]
8. Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
Riches JC; Ramsay AG; Gribben JG
Curr Pharm Des; 2012; 18(23):3389-98. PubMed ID: 22591385
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in therapy of chronic lymphocytic leukaemia.
Routledge DJ; Bloor AJ
Br J Haematol; 2016 Aug; 174(3):351-67. PubMed ID: 27291144
[TBL] [Abstract][Full Text] [Related]
10. Promising therapies for the treatment of chronic lymphocytic leukemia.
Morabito F; Recchia AG; Vigna E; De Stefano L; Bossio S; Morabito L; Pellicanò M; Palummo A; Storino F; Caruso N; Gentile M
Expert Opin Investig Drugs; 2015 Jun; 24(6):795-807. PubMed ID: 25728009
[TBL] [Abstract][Full Text] [Related]
11. Jump-starting the T cells in CLL.
Johnston JB
Blood; 2013 May; 121(20):4016-7. PubMed ID: 23682029
[TBL] [Abstract][Full Text] [Related]
12. New treatment options for chronic lymphocytic leukemia.
Delgado J; Baumann T; Santacruz R; Montserrat E
Expert Opin Pharmacother; 2014 Apr; 15(6):823-32. PubMed ID: 24559127
[TBL] [Abstract][Full Text] [Related]
13. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
14. Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.
Hofland T; Eldering E; Kater AP; Tonino SH
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484424
[TBL] [Abstract][Full Text] [Related]
15. Update on risk-stratified management for chronic lymphocytic leukemia.
Zent CS; Call TG; Hogan WJ; Shanafelt TD; Kay NE
Leuk Lymphoma; 2006 Sep; 47(9):1738-46. PubMed ID: 17064983
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in chronic lymphocytic leukemia.
Ferrajoli A; Faderl S; Keating MJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapy.
Delgado J; Baumann T; Ghita G; Montserrat E
Curr Pharm Des; 2012; 18(23):3356-62. PubMed ID: 22591384
[TBL] [Abstract][Full Text] [Related]
19. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
20. Initial therapy of chronic lymphocytic leukemia.
Eichhorst B; Cramer P; Hallek M
Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
